

November 19, 2009

National Institute of Environmental Health Sciences

Rodbell Auditorium, Rall Building

111 T.W. Alexander Drive, Research Triangle Park, NC

Technical Reports (TR) Scheduled for Review

- TR 564 1-Bromopropane (CASRN 106-94-5)
 - Previously used as an intermediate in the production of pesticides, quaternary ammonium compounds, flavors, and fragrances. Introduced as a less toxic replacement for methylene chloride in emissive applications such as vapor and immersion degreasing operations and critical cleaning of electronics and metals. Used as a relatively nonflammable, nontoxic, fast-drying, and inexpensive solvent for adhesive resins, and as a replacement for ozone-depleting refrigerants.
- TR 565 Milk Thistle Extract (CASRN 84604-20-6)
 - Milk thistle extracts are used as herbal medicines to treat a variety of diseases (e.g., liver disease) and as a food additive.
- TR 566 Diethylamine (CASRN 109-89-7)
 - Used mainly as a chemical intermediate to produce the corrosion inhibitor, *N,N*-diethylethanolamine, and to lesser extent to produce pesticides, insect repellants, pharmaceuticals, and rubber processing chemicals.
- TR 567 Ginseng (CASRN 50647-08-0)
 - Ginseng is a perennial aromatic herb widely used in herbal remedies for enhancing stamina and endurance for mental and physical performance.
- TR 563 Pulegone (CASRN 89-82-7)
 - Several essential oils that contain pulegone are used for flavoring foods, drinks, and dental products, as fragrance agents, and in herbal medicines.
- TR 536 Bis(2-chloroethoxy) methane (CASRN 111-91-1)
 - Used as a solvent and as the starting agent in the production of fungicides and polysulfide polymers.

[FR Doc. E9-23781 Filed 10-1-09; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-N-0664]

Oncologic Drugs Advisory Committee; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The meeting of the Oncologic Drugs Advisory Committee scheduled for October 6, 2009, is cancelled. This meeting was announced in the **Federal Register** of August 25, 2009 (74 FR 42907). The October 6, 2009, Oncologic Drugs Advisory Committee meeting was to discuss ApoPharma, Inc.'s new drug application (NDA) 021-825 for proposed trade name FERRIPROX (deferiprone) film-coated tablets. This meeting has been cancelled to allow time for FDA to review and resolve several outstanding issues. The agency intends to continue evaluating NDA 021-825 and, as needed, may schedule an advisory committee meeting in the future.

FOR FURTHER INFORMATION CONTACT:

Nicole Vesely, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-6793, FAX: 301-827-6776, e-mail: nicole.vesely@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512542. Please call the Information Line for up-to-date information on this meeting.

Dated: September 28, 2009.

David Horowitz,

Assistant Commissioner for Policy.

[FR Doc. E9-23764 Filed 10-1-09; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Special Conflict.

Date: October 15, 2009.

Time: 1 p.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: Melrose Hotel, 2430 Pennsylvania Avenue, NW., Washington, DC 20037.

Contact Person: Russell T. Dowell, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4128, MSC 7814, Bethesda, MD 20892. (301) 435-1850. dowellr@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Psychopathology and Adult Disorders.

Date: October 29, 2009.

Time: 8 a.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: Parc 55 Hotel, 55 Cyril Magnin Street, Market at Fifth, San Francisco, CA 94102.

Contact Person: Biao Tian, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3089B, MSC 7848, Bethesda, MD 20892. (301) 402-4411. tianbi@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Technological Innovations for Interdisciplinary Research.

Date: October 29, 2009.

Time: 3 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Parc 55 Hotel, 55 Cyril Magnin Street, Market at Fifth, San Francisco, CA 94102.

Contact Person: Biao Tian, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3089B, MSC 7848, Bethesda, MD 20892. (301) 402-4411. tianbi@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Science Education, Communication and Childhood Disorders.

Date: October 30, 2009.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Parc 55 Hotel, 55 Cyril Magnin Street, Market at Fifth, San Francisco, CA 94102.

Contact Person: Biao Tian, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge

Drive, Room 3089B, MSC 7848, Bethesda, MD 20892. (301) 402-4411.
tianbi@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 25, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-23719 Filed 10-1-09; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Meeting of the AHRQ National Advisory Council for Healthcare Research and Quality Subcommittee on Patient Safety and Medical Liability Reform Demonstrations

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Notice of public meeting.

SUMMARY: This notice announces a meeting of the National Advisory Council for Healthcare Research and Quality Subcommittee on Patient Safety and Medical Liability Reform Demonstrations.

DATES: The meeting will be held in October; specific information will be available on the AHRQ Web site at <http://www.AHRQ.gov>.

ADDRESSES: To be determined; in Washington, DC Metro area; specific information will be available at <http://www.AHRQ.gov>.

FOR FURTHER INFORMATION CONTACT: Christine Williams, Director for Strategic Partnerships, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, Maryland 20850, (301) 427-1850.

For press-related information, please contact: Karen Migdail at (301) 427-1855.

If sign language interpretation or other reasonable accommodation for a disability is needed, please contact: Mr. Michael Chew, Director, Office of Equal Employment Opportunity Program, Program Support Center, (301) 443-1144 (no later than October 15, 2009).

SUPPLEMENTARY INFORMATION:

I. Purpose

The National Advisory Council for Healthcare Research and Quality was established in accordance with Section

921 (now Section 931) of the Public Health Service Act, 42 U.S.C. 299c. In accordance with its statutory mandate, the Council is to advise the Secretary of the Department of Health and Human Services and the Director, Agency for Healthcare Research and Quality (AHRQ), on matters related to actions of AHRQ to enhance the quality, and improve the outcomes, of health care services; improve access to such services through scientific research; and promote improvements in clinical practice and in the organization, financing, and delivery of health care services.

The Council is composed of members of the public, appointed by the Secretary, and Federal ex-officio members. AHRQ's National Advisory Council on Healthcare Research and Quality (NAC) will establish a Subcommittee on Patient Safety and Medical Liability Reform Demonstrations.

The Subcommittee will be created to provide advice to the NAC for consideration and transmission to AHRQ as AHRQ undertakes the development of a new demonstration initiative that will help States and health care systems to test models that put patient safety first and work to reduce preventable injuries, foster better communication between doctors and their patients, ensure that patients are compensated in a fair and timely manner for medical injuries, while reducing the incidence of frivolous lawsuits; and reduce liability premiums.

As directed by President Obama, the Secretary of the Department of Health and Human Services (HHS) will launch a competitive three-pronged initiative that will include support for demonstration grants to States and health systems, planning grants to States and health systems, and a rapid and comprehensive review of current efforts, targeting patient safety and medical liability. Prior to finalizing the Funding Opportunity Announcement for this new initiative, the chairman of AHRQ's National Advisory Council will convene a subcommittee with diverse representation from expert and stakeholder groups to provide advice for this initiative. The date, time, location and agenda for the subcommittee meeting, which will be open to the public, will be available on the AHRQ Web site no later than two weeks in advance of such meeting. Members of the public will have the opportunity to submit comments to the subcommittee in person or in writing, and can participate in the meeting in person or via Web casting. The subcommittee will

not review individual grants nor participate in award decisions.

A roster of the Subcommittee members will be available at <http://www.AHRQ.gov>.

A more specific proposed agenda will be available before the meeting at <http://www.AHRQ.gov>.

The final agenda, including the time for public comment during the meeting, will be available on the AHRQ Web site at <http://www.AHRQ.gov>. Public comments may also be submitted in writing by e-mail, fax, mail, or hand delivery. E-mails are preferred. Please submit comments to:

Medicalliabilitydemos@AHRQ.hhs.gov.

A comment submitted by e-mail should indicate that it is in response to "Medical Liability Reform Demonstrations Subcommittee." The deadline for written comments will be posted on the AHRQ Web site. Meeting minutes will be available within 21 business days after the meeting.

Dated: September 24, 2009.

Carolyn M. Clancy,

Director.

[FR Doc. E9-23594 Filed 10-1-09; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Privacy Act of 1974; Report of an Altered System of Records; Medical Staff Credentials and Privileges Records

ACTION: Notice; correction.

SUMMARY: The Indian Health Service published a document in the **Federal Register** (FR) on September 9, 2009. The document contained three errors.

FOR FURTHER INFORMATION CONTACT: Ms. Betty Gould, Regulations Officer, 801 Thompson Avenue, TMP, Suite 450, Rockville, MD 20852, Telephone (301) 443-7899. (This is not a toll-free number.)

Correction

In the **Federal Register** of September 9, 2009 in FR Doc. E9-21422, on page 46437, in the third column, tenth line, change IRS to IHS; on page 46438, in the first column, second line, change HH to HHS; and on page 46439, in the first column, 25th line *Records Source Categories*, change IRS to IHS.